MWNA
CBIO icon

Marshall Wace North America’s Crescent Biopharma CBIO Stock Holding History

Marshall Wace North America’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-215
Closed -$204K – 1682
2018
Q4 		$204K Buy
+215
New +$259K ﹤0.01% 953

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Marshall Wace North America's CBIO Position: Q1 2019 in Review

Marshall Wace North America sold out of Crescent Biopharma (CBIO) in Q1 2019, closing a stake of 215 shares — an estimated $204K sold.

Marshall Wace North America first reported a position in CBIO in Q4 2018 and held it in 1 quarter. The position peaked at $204K in Q4 2018. 77 funds tracked by Wall St. Rank hold CBIO as of Q1 2019.

  • Marshall Wace North America reported no remaining Crescent Biopharma position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 215 Crescent Biopharma shares in Q1 2019, an estimated $204K.
  • Marshall Wace North America first reported a position in Crescent Biopharma in Q4 2018 and held it in 1 quarter.
  • Marshall Wace North America's Crescent Biopharma position peaked at $204K in Q4 2018.
  • 77 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.